Company Profile
MaxCyte Stock Price, News & Analysis
- Ticker:
- MXCT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United Kingdom and listed in the U
Stock performance
1.02 USD (-5.56%)
Close
Last updated: July 27, 2026
132M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, MXCT closed down 5.56% at $1.02. No new same-company headline was identified in the current news window.
Company overview
Business overview
MaxCyte is a cell-engineering tools company that provides electroporation platforms used in cell therapy and gene therapy development. Its products support advanced-therapy manufacturing and research workflows.
Geographic Base and Sector Classification
Headquartered in the United Kingdom and listed in the U.S. as an ADR, MaxCyte has a global life-sciences footprint.
Business Model Characteristics
The company depends on platform adoption, recurring use, and the growth of cell-therapy manufacturing demand.
Position Within the Biotechnology Landscape
MaxCyte is an enabling tools name that benefits from the broader cell-therapy ecosystem.
Future catalysts
The main thing to watch at MaxCyte is its latest development priorities. The update that sharpened the story was with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million. That is the part of the story investors will probably keep circling back to.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
- 03
- 04
- 05
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
KRYS · Source: Krystal Biotech
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of MaxCyte (MXCT)?
MaxCyte (MXCT) most recently closed at 1.02 USD, a -5.56% move versus the previous session.
What is the market cap of MaxCyte (MXCT)?
MaxCyte currently has a market capitalization of 132M USD on BioPharmSignal.
What does MaxCyte do?
MaxCyte is a cell-engineering tools company that provides electroporation platforms used in cell therapy and gene therapy development. Its products support advanced-therapy manufacturing and research workflows.
On which exchange is MXCT stock listed?
MaxCyte (MXCT) is associated with NASDAQ, United Kingdom and listed in the U, Biopharma.
What is MaxCyte?
The main thing to watch at MaxCyte is its latest development priorities.
Which conditions is MaxCyte targeting with MaxCyte?
The main thing to watch at MaxCyte is its latest development priorities.
How does MaxCyte describe recent progress with MaxCyte?
The main thing to watch at MaxCyte is its latest development priorities.
What is Core?
The update that sharpened the story was with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million.